Shots:

• The P-II trial evaluates MN-166 (ibudilast) + temozolomide (TMZ) in glioblastoma (GBM) patients (n=62) which included new & recurrent GBM patients. The 1EP of the study was the safety, tolerability & efficacy evaluated by PFS rate at 6mos.
• The result depicted PFS of 44% & 31%, whereas the combination treatment was tolerable & safe. Additionally, immunohistochemistry was examined on pre-treatment tumor tissue to evaluate MIF, pERK, Ki67, CD3, CD11b, & CD74 which showed that patients with progression had higher CD3 tumor infiltration vs those with no progression
• MN-166 (ibudilast) inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, incl. macrophage migration inhibitory factor (MIF)

Ref: MediciNova | Image: MediciNova

Related News:- MediciNova Reports the Completion of Patient Enrollment in the P-II Clinical Trial of MN-166 (ibudilast) for Glioblastoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com